Gene · 23091
Papers1,599
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 1,599
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| WTAP-VIRMA counteracts dsDNA binding of the m6A writer METTL3-METTL14 complex and maintains N6-adenosine methylation activity. | Cell Discov | 2023 | 37789010 | PubTator, text mining | PubMed |
| M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics. | Arthritis Res Ther | 2023 | 37784134 | PubTator, text mining | PubMed |
| Characteristics of m6A-related LncRNAs in breast cancer as prognostic biomarkers and immunotherapy. | J Cancer | 2023 | 37781080 | PubTator, text mining | PubMed |
| Role of histone lactylation interference RNA m6A modification and immune microenvironment homeostasis in pulmonary arterial hypertension. | Front Cell Dev Biol | 2023 | 37771377 | PubTator, text mining | PubMed |
| A novel signature for predicting prognosis and immune landscape in cutaneous melanoma based on anoikis-related long non-coding RNAs. | Sci Rep | 2023 | 37770477 | PubTator, text mining | PubMed |
| Epigenetic regulation of programmed cell death in hypoxia-induced pulmonary arterial hypertension. | Front Immunol | 2023 | 37753070 | PubTator, text mining | PubMed |
| Interaction between N6-methyladenosine modification and the tumor microenvironment in colorectal cancer. | Mol Med | 2023 | 37737134 | PubTator, text mining | PubMed |
| A pan-cancer analysis reveals the diagnostic and prognostic role of CDCA2 in low-grade glioma. | PLoS One | 2023 | 37733705 | PubTator, text mining | PubMed |
| Comprehensive analyses of m6A RNA methylation patterns and related immune microenvironment in idiopathic pulmonary arterial hypertension. | Front Genet | 2023 | 37732317 | PubTator, text mining | PubMed |
| A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer. | J Ovarian Res | 2023 | 37730669 | PubTator, text mining | PubMed |
| YTHDF3as a prognostic predictive biomarker of thyroid cancer and its correlation with immune infiltration. | BMC Cancer | 2023 | 37726690 | PubTator, text mining | PubMed |
| Regulation of m6A modification on ferroptosis and its potential significance in radiosensitization. | Cell Death Discov | 2023 | 37714846 | PubTator, text mining | PubMed |
| KIAA1429/VIRMA promotes breast cancer progression by m6 A-dependent cytosolic HAS2 stabilization. | EMBO Rep | 2023 | 37705505 | PubTator, text mining | PubMed |
| The current landscape of m6A modification in urological cancers. | PeerJ | 2023 | 37701836 | PubTator, text mining | PubMed |
| Abnormal genetic and epigenetic patterns of m6A regulators associated with tumor microenvironment in colorectal cancer. | Transl Cancer Res | 2023 | 37701104 | PubTator, text mining | PubMed |
| Dysregulation and implications of N6-methyladenosine modification in renal cell carcinoma. | Curr Urol | 2023 | 37692138 | PubTator, text mining | PubMed |
| The m6A-related gene signature stratifies poor prognosis patients and characterizes immunosuppressive microenvironment in hepatocellular carcinoma. | Front Immunol | 2023 | 37691948 | PubTator, text mining | PubMed |
| METTL16 controls Kaposi's sarcoma-associated herpesvirus replication by regulating S-adenosylmethionine cycle. | Cell Death Dis | 2023 | 37673880 | PubTator, text mining | PubMed |
| Emerging role of METTL3 in inflammatory diseases: mechanisms and therapeutic applications. | Front Immunol | 2023 | 37671161 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA. | PeerJ | 2023 | 37663284 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23091/papers?page=10